Non-Hodgkin's lymphoma - rituximab (TA65)
NICE has made the following recommendations about the use of rituximab (Mab Thera) to treat aggressive non-Hodgkin’s lymphoma.
NICE has recommended that rituximab and the CHOP combination of chemotherapy medicines (a combination of cyclophosphamide, doxorubicin, vincristine and prednisolone) should be the first treatment considered for people with diffuse large-B-cell lymphoma that is at stage 2, 3 or 4. (These people should have CD20 on their B cells – see full guidance document.)
Rituximab is not recommended for people who are unable to have chemotherapy with the CHOP combination.
NICE has said that rituximab should only be used in people with diffuse large-B-cell lymphoma in stage 1 if they are being treated as part of a clinical study. This is because, at present, there isn’t enough evidence that rituximab works well or that it works well enough considering its cost in this group of people for it to be used routinely.
The last recommendation from NICE is that treatment with rituximab and CHOP should be supervised by a doctor who has specialised in the treatment of lymphomas.
- TA65 Non-Hodgkin's lymphoma - rituximab: guidance (web format)
- TA65 Non-Hodgkin's lymphoma - rituximab: summary
This page was last updated: 10 February 2011
- Web format
- Full Guidance (PDF)
- TA65 Rituximab ar gyfer lymffoma ymladdgar nad yw´n lymffoma math Hodgkin: deall canllawiau NICE
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.